19
Jan
2010
Marval Biosciences, Inc.: Series B $2.5M
Posted in I - Series B, Q - 4Q09, R - WEST, X - Imaging, XX - CA
Marval Biosciences (San Diego, CA) a preclinical-stage biopharma company focused on the reformulation of contrast dyes for CT scans using liposomal nanoparticles, closed a $2.5M Series B financing. Participants include DFJ Frontier and DFJ Mercury.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.
OnBioVC PARTNERS
-
Where is OnBioVC Content Consumed?
